33 results about "Obstructive lung disease" patented technology

The invention discloses a difluoromethoxy phenyl PDE4 inhibitor and application thereof. The compound has the effects of resisting inflammation, treating psoriasis, treating lung injury, treating chronic obstructive pulmonary disease and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a nauclea officinalis extract in preparation of a medicine for treating chronic obstructive pulmonary diseases. Experimental research shows that the nauclea officinalis extract is used for treating the chronic obstructive pulmonary disease, can inhibit lung inflammation of a patient suffering from the chronic obstructive pulmonary disease and improve the lung function and emphysema injury of the chronic obstructive pulmonary disease, can be used for preventing and treating the chronic obstructive pulmonary disease, and can be used for preventing and treating the chronic obstructive pulmonary disease. And a new strategy is provided for the development of medicines for treating chronic obstructive pulmonary diseases.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and / or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and / or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and / or open wound patients.

Provided is a pharmaceutical for lung regeneration, the pharmaceutical containing vascular endothelial stem cells. Also provided is a method for producing an alveolar organoid, the method comprising a step for three-dimensional co-culture of vascular endothelial stem cells and alveolar epithelial cells. This pharmaceutical for lung regeneration is useful in the treatment of lung disease accompanied by alveolar damage, such as chronic obstructive lung diseases, infectious lung diseases, and pulmonary fibrosis.

The invention relates to the technical field of biological medicines, in particular to application of a CD20 inhibitor in treatment of chronic obstructive pulmonary diseases. The CD20 inhibitor can remarkably improve emphysema and small airway collagen deposition in chronic obstructive pulmonary diseases, inhibit expression of inflammatory factors IL-6 and TNF-alpha in lung tissue, reduce the concentration of chemotactic factors CXCL2 in bronchoalveolar lavage fluid and relieve lung inflammation, and the treatment effect is remarkable. Obviously, CD20 can become a potential clinical treatment target of chronic obstructive pulmonary disease.

The invention belongs to the field of nursing science, and particularly relates to an acute exacerbation malnutrition risk prediction model for an old chronic obstructive pulmonary disease patient and a construction method of the acute exacerbation malnutrition risk prediction model, which are used for establishing a rapid and accurate prediction model for acute exacerbation malnutrition risk screening and evaluation of the old chronic obstructive pulmonary disease patient. The invention discloses a model for predicting the risk of acute exacerbation dystrophy of an old chronic obstructive pulmonary disease patient. The risk prediction model is a multivariate Logistic regression model: P =-12.845 + 1.022 * age + 0.339 * ethnic + 0.077 * educated degree + 0.683 * gastrointestinal tract symptom + 0.035 * height-0.126 * body mass index + 1.045 * partial pressure of carbon dioxide-0.077 * chloride ion-0.017 * serum albumin-0.004 * prealbumin + 0.005 * hypersensitive C reaction protein + 0.479 * lymphocyte number. According to the acute exacerbation malnutrition risk prediction model for the patient with the chronic obstructive pulmonary disease of the aged and the construction method thereof, the prediction model for rapidly and accurately screening and evaluating the acute exacerbation malnutrition risk of the patient with the chronic obstructive pulmonary disease of the aged is established.

This invention provides a traditional Chinese medicine composition for clearing the lungs and relieving asthma, its granules, and their applications, relating to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for clearing the lungs and relieving asthma of this invention is prepared from the following raw materials in the indicated weight proportions: Ephedra 8-12g, Earthworm 8-12g, Bitter Apricot Kernel 8-12g, Mulberry Bark 8-12g, Coltsfoot Flower 13-18g, Stemona 13-18g, Platycodon Root 8-12g, Prepared Pinellia Rhizome 8-12g, Tangerine Peel 8-12g, Ginkgo Root 8-12g, Scutellaria Root 13-18g, Perilla Seed 13-18g, Trichosanthes Peel 25-35g, Peucedanum Root 8-12g, and Belamcanda Rhizome 8-12g. The traditional Chinese medicine formula provided by this invention has good clinical efficacy in treating chronic obstructive pulmonary disease, with high clinical control and efficacy rates, and a high overall effective rate.

The application belongs to the technical field of medicine, and discloses application of a perilla leaf extract in preparation of a medicine for treating and / or preventing asthma-chronic obstructive pulmonary disease (ACO). The perilla leaf extract has a significant curative effect in treating and / or preventing ACO disease, can significantly improve aggregation of inflammatory cells in the lung of an ACO mouse and generation levels of inflammatory factors, and improve lung function and pathological changes of lung tissue inflammation; in addition, the perilla leaf extract can significantly inhibit generation of neutrophil inflammatory factors TNF-alpha, IL-6 and IL-1beta, and inhibit generation of an eosinophil inflammatory factor TNF-alpha.

The invention discloses an application of adenosine in preparing or preventing a chronic obstructive pulmonary disease, the chronic obstructive pulmonary disease refers to an acute exacerbation stage of the chronic obstructive pulmonary disease, and the acute exacerbation stage of the chronic obstructive pulmonary disease is caused by streptococcus pneumoniae; the medicine is used for inhibiting cell activation and proinflammatory factor release through an A2AR receptor. The invention provides a powerful scientific basis for application of adenosine in preparation of related drugs in treatment and prevention of lung diseases, especially chronic obstructive pulmonary diseases.

The invention discloses a heart and lung condition detection system for a patient with chronic obstructive pulmonary disease based on virtual reality, and belongs to the technical field of intelligent medical treatment. The problem that the cardiopulmonary state of a patient in daily activities is difficult to comprehensively reflect in the prior art is solved, data packet loss is found in time by detecting the time interval of the data stream, and data transmission errors are reduced in combination with monitoring of the data transmission rate; data are analyzed in combination with physiological rules, and untrusted data are removed; therefore, a reliable data basis is provided for cardiopulmonary function evaluation, and the rehabilitation effect can be improved. A multi-dimensional respiratory cycle portrait of a chronic obstructive pulmonary disease patient is analyzed in real time by constructing a cardiopulmonary function prediction model, and an abnormal mode deviating from a baseline is accurately recognized; a user behavior analysis mechanism is introduced to evaluate the psychological state and the rehabilitation effect, personalized early warning information and rehabilitation suggestions are generated, it is ensured that a patient can be intervened in time when abnormity occurs, and meanwhile the monitoring burden of medical staff is relieved.

The invention discloses application of an MUC1-C segment in preparation of a medicine for preventing or treating chronic obstructive pulmonary disease, and belongs to the technical field of protein functions and targeted medicine development. The MUC1-C protein level in the lung tissue and alveolar epithelial cells of a COPD patient is detected, and cell experiments and animal experiments jointly prove that down-regulation of MUC1-C expression is significantly related to the aging level of the lung tissue, the level of differentiation from AT2 cells to AT1 cells, the inflammation level, mitochondrial dysfunction and reduction of lung functions. MUC1-C overexpression can effectively relieve deterioration of the pathological process. The invention can be applied to the fields of research and development of new drugs and new technologies for diagnosing, preventing and treating chronic obstructive pulmonary disease, and the like.

The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.

The invention provides an intelligent early warning intervention system for chronic obstructive pulmonary diseases, and relates to the technical field of medical instruments. Comprising a core host, the core host is integrated with an active multi-modal sensor arm and an integrated drug delivery arm, a patient can be actively guided to enter a standardized test posture, and high-quality multi-modal physiological data such as lung function, blood oxygen and breath sound are synchronously collected; an intelligent medicine bin and an automatic delivery mechanism are arranged in the intelligent medicine box, and accurate taking, delivery and auxiliary inhalation of medicine can be completed after early warning is triggered. The standardized seat assists in fixing the sitting posture of a patient through a physical guiding structure, and the wearable monitoring vest achieves respiratory rhythm monitoring and auxiliary sputum excretion. According to the system, all the modules are cooperated through the central controller, and a complete entity closed loop from standard monitoring to intelligent early warning to automatic intervention is constructed. The system effectively solves the problems that household lung function monitoring data is unreliable and intervention is difficult to execute after early warning, and the timeliness, safety and patient compliance of chronic disease management are remarkably improved.

The invention discloses application of a reagent for knocking down NOD1 in preparation of a medicine for treating chronic obstructive pulmonary disease, and relates to the technical field of biology. By knocking down NOD1, lung dysfunction caused by the chronic obstructive pulmonary disease can be improved, the lung function is improved, and an obvious prevention and treatment effect on the chronic obstructive pulmonary disease is achieved.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The application discloses a use of taibai araloside in treating hypoxic pulmonary arterial hypertension. In the use of hypoxia to induce pulmonary arterial hypertension, it is found that the taibai araloside can reduce right ventricular pressure and right heart hypertrophy index, and inhibit pulmonary arterial remodeling; the taibai araloside reduces the expression and activity of ACE in the lung in a concentration-dependent manner, and corrects the disorder of the RAS system in the lung caused by hypoxic pulmonary arterial hypertension. Moreover, a monomer component of the taibai araloside, anemarrhena asphodeloides glycoside and chizhenshan saponin IVa, has a stable combination with ACE. The results show that the taibai araloside has the potential to be developed into a drug for preventing and treating hypoxic pulmonary arterial hypertension in the clinic, and also provides a prevention and treatment strategy for interstitial lung disease, chronic obstructive pulmonary disease, sleep apnea syndrome, chronic high altitude disease and neonatal respiratory disease.

The present invention provides an obstructive lung disease biomarker and a method for using the same. This method for examining obstructive lung disease includes a step (1) of detecting at least one protein selected from the group consisting of a protein group (A), a protein group (B), a protein group (C), and a protein group (D) in a sample collected from a subject, wherein the sample is an extracellular vesicle from exhaled air and / or body fluid on the respiratory surface, or exhaled air and / or body fluid on the respiratory surface.

The invention discloses a viscera regulating and lung nourishing formula for chronic obstructive pulmonary disease complicated with osteopenia, and belongs to the technical field of traditional Chinese medicines. The invention discloses a formula for regulating viscera and nourishing lung. The formula is prepared from the following traditional Chinese medicines: 10-20 parts of codonopsis pilosula, 6-15 parts of rhizoma atractylodis macrocephalae fried with bran, 6-15 parts of white mulberry root-bark, 1.5-6 parts of bulbus fritillariae cirrhosae, 10-20 parts of fructus lycii, 10-20 parts of semen cuscutae, 12-20 parts of adenophora tetraphylla, 12-20 parts of radix glehniae, 6-15 parts of radix paeoniae alba, 9-18 parts of raw astragalus membranaceus, 9-12 parts of officinal magnolia bark, 9-18 parts of roasted aster, 9-18 parts of roasted tussilago farfara and 6-15 parts of ligusticum wallichii. An oral preparation can be prepared by taking the formula as a raw material and adding pharmaceutically acceptable auxiliary materials, and the oral preparation can be divided into three types, namely a solid, a liquid and a paste, and can be specifically selected from a plurality of dosage forms, such as decoction, granules and the like. The viscera regulating and lung nourishing prescription can be used for preparing a medicine for treating chronic obstructive pulmonary disease stable phase combined bone mass reduction, plays a role by regulating bone metabolism balance, is reasonable in compatibility and diverse in dosage form, and provides a new choice for clinical treatment.

Disclosed herein are compounds useful for treating obstructive lung diseases. The compounds are TAS2Rs agonists and may further be used to treat disorders and conditions implicated by TAS2R. In some instances the disclosed compounds can be used to treat asthma.

The invention discloses a traditional Chinese medicine composition for treating or adjunctively treating chronic obstructive pulmonary diseases. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20-40 parts of astragalus membranaceus, 10-30 parts of fried codonopsis pilosula, 10-14 parts of fried bighead atractylodes rhizome, 13-18 parts of poria cocos, 10-14 parts of bamboo juice pinellia ternate, 7-11 parts of pericarpium citri reticulatae, 10-14 parts of radix peucedani, 10-14 parts of cortex moutan and 1-5 parts of honey-fried licorice root. Tests prove that the traditional Chinese medicine composition and the traditional Chinese medicine extract can improve lung functions, relieve lung inflammatory cell infiltration, inhibit generation of inflammatory factors and reduce airway inflammatory response; in addition, diaphragm pathological injury can be relieved, formation of autophagosome is reduced, expression of ubiquitin-proteasome pathway symbolic protein is inhibited, and diaphragm atrophy is delayed, so that the chronic obstructive pulmonary disease is comprehensively treated, a new thought is provided for treatment of respiratory system diseases such as the chronic obstructive pulmonary disease, and the pharmaceutical composition is worthy of popularization and application. The traditional Chinese medicine composition has important clinical application and market promotion values.

The invention relates to the technical field of lung disease treatment, in particular to a medicine for treating chronic obstructive pulmonary disease and application. The pharmaceutical composition can obviously inhibit lung inflammatory cell infiltration and inflammatory factor generation of patients with chronic obstructive pulmonary diseases and induce malignant cell apoptosis, effectively regulate TNF-alpha, IL-6, calcium and phosphorus levels of the patients with chronic obstructive pulmonary diseases, increase the walking distance of the patients with chronic obstructive pulmonary diseases and improve the curative effect of the patients with chronic obstructive pulmonary diseases. The pharmaceutical composition can be used for effectively treating chronic obstructive pulmonary disease patients and improving prognosis conditions of the chronic obstructive pulmonary disease patients, and is safe to use, easy to control and convenient for clinical application and popularization.

The invention belongs to the field of biological medicine, and particularly relates to a scutellarin and luteolin compatible composition and application thereof. In particular discloses a scutellarin and luteolin compatible composition as shown in formulas (I) and (II), and the scutellarin and luteolin compatible composition is applied to treatment and / or prevention of chronic obstructive pulmonary diseases. The screened scutellarin and luteolin compatible composition is simple in preparation method, has a remarkable synergistic treatment effect on the chronic obstructive pulmonary disease, and has a remarkable treatment effect on airway inflammation and lung function impairment of a mouse with the chronic obstructive pulmonary disease induced by a cigarette smoke extract; meanwhile, the composition shows a remarkable inhibiting effect on a neutrophile granulocyte extracellular trap net released by LPS-induced primary mouse bone marrow neutrophile granulocyte, TNF-alpha and IL-6 in vitro, the two medicines have a synergistic effect, the improvement effect is obviously superior to that of a single medicine, and the compatible composition has a relatively high development and application value in treatment of the chronic obstructive pulmonary disease.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and a preparation method and application thereof. Specifically, the traditional Chinese medicine composition for treating the chronic obstructive pulmonary disease is prepared from the following raw materials in parts by weight: 20-40 parts of calyx seu fructus physalis, 20-40 parts of thesium chinense, 10-25 parts of flos farfarae, 10-20 parts of white mulberry root-bark, 30-50 parts of ginseng and 20-40 parts of ligusticum wallichii. The traditional Chinese medicine composition is prepared according to the traditional Chinese medicine thinking, can clear away lung heat without hurting vital energy, reduce phlegm and stasis, dredge lung collaterals, tonify qi and activate blood to treat both symptoms and root causes, and has the effects of resisting inflammation, relieving asthma and improving lung functions, so that the traditional Chinese medicine composition is used for treating the chronic obstructive pulmonary disease. Tests prove that the compound has anti-inflammatory and anti-oxidation effects on the cellular level, and can inhibit the process of the mouse chronic obstructive pulmonary disease induced by cigarette smoke on the animal level, so that the compound has good practical application value.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention discloses an alpha, beta unsaturated ketone substituted chromone derivative of which the structure is shown as a formula I or pharmaceutically acceptable salt and isomer I thereof. The compound can realize efficient selective inhibition on a BLT1 receptor through a specific molecular action mechanism, shows nanomole-level BLT1 inhibition activity and excellent selectivity, and meanwhile, shows a remarkable treatment effect in acute lung injury, chronic obstructive pulmonary disease and sepsis models. The invention discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of a BLT1 inhibitor, and also discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of the BLT1 inhibitor. The invention discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of medicines for treating acute lung injury, chronic obstructive pulmonary disease and sepsis, and also discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of medicines for treating acute lung injury, chronic obstructive pulmonary disease and sepsis.

The application provides a compound medicine for relieving cough and asthma in atomization treatment of respiratory system and a preparation and application thereof. The medicine is prepared from white ginkgo, ephedra and other Chinese medicinal materials as main raw materials, and further comprises complex bacteria, an osmotic pressure regulator and a dissolving agent. The complex bacteria are composed of cordyceps sinensis, bamboo lotus and pine olive in a specific mass ratio, the osmotic pressure regulator is glucose and glycerol in a specific ratio, and the dissolving agent can be selected from multiple kinds. The preparation method comprises multiple steps, including unique processes such as extraction of medicinal materials, salt modification and ultrasonic extraction. Through clinical tests, compared with a control group and a placebo group, the compound medicine can significantly improve the lung function related indexes of patients, reduce the inflammatory factor level, and effectively relieve the cough and asthma symptoms through a visual analogue scale method. The medicine can be used for preparing an atomization inhalation medicine for treating bronchial asthma, chronic obstructive pulmonary disease and other respiratory diseases, and has a good application prospect.

The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.

The application relates to the technical field of combined medicines, and discloses application of a Dachaihu decoction combined with crocin in preparation of AECOPD medicines, which comprises the Dachaihu decoction and crocin, and the mass ratio of the Dachaihu decoction to the crocin is 284:5; wherein the mass of the Dachaihu decoction is recorded according to the mass of medicinal materials. The Dachaihu decoction has the advantages of small side effect and high safety in treatment of AECOPD, and the crocin can improve the lung function of patients in the acute exacerbation period of chronic obstructive pulmonary disease by down-regulating the expression of NLRP3, inhibit oxidation stress and inflammatory reaction, and inhibit alveolar epithelial cell apoptosis. The Dachaihu decoction is creatively combined with the crocin, and the combination can play a synergistic role in treatment of the acute exacerbation period of chronic obstructive pulmonary disease, so that the Dachaihu decoction combined with the crocin has an application prospect of development into a medicine for treatment of the acute exacerbation period of chronic obstructive pulmonary disease.

The invention discloses an application ointment for chronic cough and asthma diseases, a preparation method and a use method, which can effectively treat chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease, bronchiectasis, chronic cough, pulmonary fibrosis and the like with cough and asthma as main symptoms, and is non-invasive, convenient and non-irritant to skin. The application ointment for treating the chronic cough and asthma diseases is prepared from the following raw materials in percentage by mass: 12 to 13 percent of herba ephedrae, 12 to 13 percent of semen armeniacae amarae, 24 to 26 percent of perillaseed, 12 to 13 percent of semen brassicae, 12 to 13 percent of semen raphani, 5 to 7 percent of datura seed, 12 to 13 percent of earthworm, 1 percent of sesame oil and 2 percent of ginger juice.